newsfilter
← Latest News
GlobeNewswire·

Kneat Announces Record Revenue for First Quarter 2026

KSIOF
  • Kneat reported Q1 2026 total revenue of $18.0 million, a 22% year-over-year increase from $14.7 million in Q1 2025.
  • Annual Recurring Revenue (ARR) reached $76.4 million at March 31, 2026, representing a 20% year-over-year growth.
  • Gross profit grew 28% year-over-year to $14.0 million, with gross margin expanding to 78% from 74% in the prior year period.
  • Net loss for the quarter was $3.9 million, contrasting with a net profit of $2.1 million in Q1 2025.
  • EBITDA for Q1 2026 was $0.8 million, down from $5.9 million in the same period last year.
  • Adjusted EBITDA increased to $2.7 million in Q1 2026, up from $2.3 million in Q1 2025.
  • Recent business wins include digital validation contracts with a European biopharma leader, a US pharmaceutical packaging manufacturer, and a major European CDMO.
  • Kneat achieved record attendance at its VALIDATE 2026 user conference in April, highlighting feedback on native embedded AI capabilities.
  • The company secured top positions in three G2 Software Review categories for Pharma and Biotech, marking the third consecutive year of first-place rankings.
  • The 2026 State of Validation study revealed record workload demands, high ROI satisfaction among digitizers, and digital maturity as a prerequisite for responsible AI deployment.
  • Kneat will host a quarterly conference call on May 14, 2026, at 9:00 a.m. ET to discuss results with analysts and investors.
  • Cash and cash equivalents stood at $51.5 million as of March 31, 2026, up from $48.7 million at December 31, 2025.
  • Contract liabilities increased significantly to $39.1 million in current liabilities, reflecting strong future revenue recognition potential.